Skip to content
drillr.ai

RPRX

Royalty Pharma plc

NASDAQ · USHealthcareBiotechnology
$57.30-1.52%

Price as of Jul 20, 2026

RPRX news

Royalty Pharma plc news

A server-rendered, paginated timeline of the latest available company news.

  1. Royalty Pharma declares third quarter 2026 dividend

    NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceu

    Globe Newswire ·

  2. Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

    NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will honor scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients’ lives. It will include a $1 million award distributed among one or more established scientists whose work has trans

    Globe Newswire ·

  3. Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

    NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. JNJ‑4804 is a novel co‑antibody therapy that blocks the complementary interleukin‑23 (IL‑23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of c

    Globe Newswire ·

  4. Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

    NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma. “Lucas’s appointment marks a significant step in our commitment to implementing cutting‑edge technology across our platform,” said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of R

    Globe Newswire ·

  5. Royalty Pharma Announces Expansion of Leadership Team

    NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team. Greg Butz will join Royalty Pharma as Executive Vice President, Partnering & Investments, effective June 2026. Greg joins Royalty Pharma from Bank of America, where he was the Global Co-Head of Healthcare Investment Banking. “We are thrilled that Greg will join Royalty Pharma and strengthen our leadership team,” said Pablo Legorreta, Chief Executive Officer and Chai

    Globe Newswire ·

  6. Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

    Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform PR Newswire NEW YORK, March 3, 2026 NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healt

    PR Newswire ·

  7. Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

    * Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid * Zymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceased * Proceeds strengthen Zymeworks’ balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acq

    Globe Newswire ·

  8. Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

    * Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid * Zymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceased * Proceeds strengthen Zymeworks’ balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acq

    Globe Newswire ·

  9. Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260226:nGNX2W6bNs&default-theme=true NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 46(th) Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://ww

    Globe Newswire ·